FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:937-938 March 31, 1994 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lewis, E. J.

To the Editor: Lewis et al. (Nov. 11 issue)¹ report that captopril was beneficial in patients with diabetic nephropathy. We have several questions.

Since base-line urinary protein excretion was significantly lower in the captopril group, is it possible that the less severe nephropathy in this group accounted for its slower progression?

Does the recommendation that angiotensin-converting-enzyme inhibitors be given to patients with diabetic nephropathy mean that these agents should be given in preference to diuretics and beta-adrenergic antagonists? The latter two types of drugs may have more side effects, but they are the only drugs that have been proved effective . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.